Erythema Multiforme-Like Eruption Induced After Immune Checkpoint Inhibitor and Target Therapy in a Patient with Malignant Melanoma – A Case Report
By:
References
- Weber JS, Yang JC, Atkins MB, Disis ML. Toxicities of Immunotherapy for the Practitioner. J Clin Oncol. 2015 Jun 20;33(18):2092-9. doi: 10.1200/JCO.2014.60.0379.
- Michielin O, van Akkooi ACJ, Ascierto PA, et al. ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo. org. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019 Dec 1; 30(12):1884-1901. doi: 10.1093/annonc/mdz411.
- von Hebra F. Acute Exantheme und Hautkrankheiten, Verlag von Ferdinand von Enke, Erlangen, 1860.
- Paulino L, Hamblin DJ, Osondu N, Amini R. Variants of Erythema Multiforme: A Case Report and Literature Review. Cureus. 2018 Oct 16;10(10):e3459. doi: 10.7759/cureus.3459.
- Mockenhaupt M. Severe drug-induced skin reactions: clinical pattern, diagnostics and therapy. J Dtsch Dermatol Ges. 2009 Feb;7(2):142-60; quiz 161-2. English, German. doi: 10.1111/j.1610-0387.2008.06878.x.
- Damevska K, Vassileva S, Kostadinova-Kunovska S. Erythema Multiforme, Stevens–Johnson Syndrome, and Toxic Epidermal Necrolysis. In: Smoller, B., Bagherani, N. (eds) Atlas of Dermatology, Dermatopathology and Venereology. Springer, Cham. 2022. https://doi.org/10.1007/978-3-319-53808-2_60
- Martin-Liberal J, Kordbacheh T, Larkin J. Safety of pembrolizumab for the treatment of melanoma. Expert Opin Drug Saf. 2015 Jun;14(6):957-64. doi: 10.1517/14740338.2015.1021774.
- Garbe C, Eigentler TK. Vemurafenib. Recent Results Cancer Res. 2018; 211:77-89. doi: 10.1007/978-3-319-91442-8_6.
- Wantz M, Spanoudi-Kitrimi I, Lasek A. Nécrolyse épidermique toxique au vemurafenib [Vemurafenib-induced toxic epidermal necrolysis]. Ann Dermatol Venereol. 2014 Mar;141(3):215-8. French. doi: 10.1016/j.annder.2013.10.054.
- McFarlane T, Rehman N, Wang K, et al. Cutaneous toxicities of new targeted cancer therapies: must know for diagnosis, management, and patient-proxy empowerment. Ann Palliat Med. 2020 May;9(3):1296-1306. doi: 10.21037/apm.2019.08.05.
- Haanen JBAG, Carbonnel F, Robert C, et al. ESMO Guidelines Committee. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017 Jul 1;28(suppl_4):iv119-iv142. doi: 10.1093/annonc/mdx225. Erratum in: Ann Oncol. 2018 Oct 1;29(Suppl 4):iv264-iv266.
- Hashimoto H, Ito T, Ichiki T, et al. The Clinical and Histopathological Features of Cutaneous Immune-Related Adverse Events and Their Outcomes. J Clin Med. 2021 Feb 12;10(4):728. doi: 10.3390/jcm10040728.
- Sibaud V, Meyer N, Lamant L, et al. Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies. Curr Opin Oncol. 2016 Jul;28(4):254-63. doi: 0.1097/CCO.0000000000000290.
- Sibaud V. Dermatologic Reactions to Immune Checkpoint Inhibitors: Skin Toxicities and Immunotherapy. Am J Clin Dermatol. 2018 Jun;19(3):345-361. doi: 10.1007/s40257-017-0336-3.
- Coleman EL, Olamiju B, Leventhal JS. The life-threatening eruptions of immune checkpoint inhibitor therapy. Clin Dermatol. 2020 Jan-Feb;38(1):94-104. doi: 0.1016/j.clindermatol.2019.10.015.
- Geisler AN, Phillips GS, Barrios DM, et al. Immune check-point inhibitor-related dermatologic adverse events. J Am Acad Dermatol. 2020 Nov;83(5):1255-1268. doi: 10.1016/j. jaad.2020.03.132.
- Nomura H, Takahashi H, Suzuki S, et al. Unexpected recalcitrant course of drug-induced erythema multiforme-like eruption and interstitial pneumonia sequentially occurring after nivolumab therapy. J Dermatol. 2017 Jul;44(7):818-821. doi: 10.1111/1346-8138.13810.
Language: English
Page range: 50 - 55
Submitted on: Sep 18, 2024
Accepted on: Oct 22, 2024
Published on: May 15, 2025
Published by: Sofia Medical University
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
Related subjects:
© 2025 P. Vasilev, S. Ramadan, I. Yordanova, E. Simeonov, published by Sofia Medical University
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.